BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

Abstract

In patients with PTC, BRAF mutation is associated with poorer clinicopathological outcomes and independently predicts recurrence. Therefore, BRAF mutation may be a useful molecular marker to assist in risk stratification for patients with PTC.